Palisade Bio (NASDAQ:PALI – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.
Volatility & Risk
Palisade Bio has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Earnings & Valuation
This table compares Palisade Bio and Milestone Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palisade Bio | $250,000.00 | 1,401.13 | -$16.78 million | ($0.48) | -4.19 |
| Milestone Pharmaceuticals | $1.55 million | 84.34 | -$63.06 million | ($0.69) | -1.52 |
Palisade Bio has higher earnings, but lower revenue than Milestone Pharmaceuticals. Palisade Bio is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Palisade Bio and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palisade Bio | N/A | -33.47% | -31.79% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Institutional and Insider Ownership
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Palisade Bio and Milestone Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palisade Bio | 1 | 0 | 7 | 2 | 3.00 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Palisade Bio currently has a consensus target price of $9.00, indicating a potential upside of 347.76%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 509.52%. Given Milestone Pharmaceuticals’ higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Palisade Bio.
Summary
Palisade Bio beats Milestone Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
